Skip to main content
Toggle navigation
Login
Search
Home
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
M
Ma, Huilin
Bristol Myers Squibb
(
S-049
)
Understanding PK/PD relationship of CD19 CAR-T (BMS-986353) in Systemic Lupus Erythematosus (SLE) using a mechanistic quantitative pharmacology framework
Huilin Ma
Favorite
Ma, Jessica
(
T-078
)
Exposure-Response Modeling of Efficacy and Safety Endpoints of Sarilumab in Pediatric Patients with Polyarticular-Course Juvenile Arthritis
Jessica Ma
Favorite
Mapder, Tarunendu
Bristol Myers Squibb
(
M-013
)
QSP Model of Nivolumab in Combination with Bispecific T Cell Engagers predicts Enhanced Anti-Tumor Immunity
Tarunendu Mapder
Favorite
Marcinowicz, Agnieszka
Premier Research
(
M-102
)
Strategic application of PK modeling in 505(b)(2) development for a new pediatric formulation
Agnieszka Marcinowicz
Favorite
Masters, Joanna
Pfizer Inc
(
M-071
)
Dose optimization framework to estimate benefit-risk for oncology compounds: an integrated population model framework incorporating PK, safety, efficacy and impact of dose modifications
Joanna Masters
Favorite
Mathew, Shibin
Pfizer Inc.
(
M-062
)
Utilizing MechDermA model for early feasibility analysis in topical drug discovery
Shibin Mathew
Favorite
(
T-054
)
Retrospective analysis of systemic and dermal PK of several anti-inflammatory topicals using SimCYP MechDermA model explains the observed clinical efficacy of successful and failed drugs
Shibin Mathew
Favorite
Mbuguiro, Wangui
AstraZeneca
(
M-046
)
Evaluating the feasibility of virtual controls in organ impairment studies using modeling and simulation
Wangui Mbuguiro
Favorite
McCune, Jeannine
Merck
(
T-072
)
Population pharmacokinetic model-informed dose selection for exogenous hemopexin (CSL889) in patients with sickle cell disease
Jeannine McCune
Favorite
McDougall, Emily
(
M-032
)
Optimizing Pediatric Doses for Weight-Based Dosing Regimens Under Constraints
Emily McDougall
Favorite
Meyer, Lyndsey
Pfizer
(
S-092
)
Developing a translational framework to predict clinical weight loss for novel or combination incretin therapies
Lyndsey Meyer
Favorite
Mitra, Amitava
Kura Oncology, Inc
(
S-003
)
Population PK Modeling of Ziftomenib and its Metabolites in Healthy Subjects and in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amitava Mitra
Favorite
(
S-004
)
Exposure-Response Analysis of Ziftomenib in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Amitava Mitra
Favorite
Miyazawa, Kenji
Moderna, Inc.
(
M-017
)
Comparative Sensitivity Analysis of Semi-mechanistic and QSP Models of Humoral Response Following Vaccination
Kenji Miyazawa
Favorite
(
M-018
)
Construction of a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model to Facilitate the Design of LNP based mRNA Therapeutics for Secreted Protein Targets with Applications to Anti-Viral Therapies
Kenji Miyazawa
Favorite
(
M-079
)
Deriving allometric scaling rules and providing Insights into the dynamics of LNP based mRNA therapeutics with an exactly solvable mathematical model
Kenji Miyazawa
Favorite
Mizuno, Morihiko
interdisciplinary Biology Laboratory (iBLab), Division of Natural Science, Graduate School of Science, Nagoya University
(
S-080
)
Fluorescence timer-based analysis of latency-reversing agent effectiveness in HIV
Morihiko Mizuno
Favorite
Moore, Helen
University of Florida
(
T-056
)
A novel mechanistic mathematical model of liver transplant immune dynamics predicts important drivers of patient outcome
Helen Moore
Favorite
Müller-Widmann, David
PumasAI
(
M-099
)
Case Study: Parameter Estimation of an NLME-QSP Model
David Müller-Widmann
Favorite
Muthukrishnan, Venkateswari
CSL Behring
(
T-085
)
Pharmacometric Modeling of Clazakizumab in Patients Undergoing Maintenance Dialysis
Venkateswari Muthukrishnan
Favorite
Myers, Renee
Rosa & Co. LLC
(
T-012
)
Evaluation of Parallel Tempering for Efficient Generation of Virtual Populations
Renee Myers
Favorite
